{"transactions":[{"id":4624650,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-22T20:20:02.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":126418,"price":8.95,"value":1131441.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":138668,"source":{"system":"sec-edgar","filing":"0001193125-26-397951","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526397951/ownership.xml","form_type":"4"}},{"id":725611,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:42:22.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045833","document":"wk-form4_1782510140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045833/wk-form4_1782510140.xml","form_type":"4"}},{"id":874052,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T23:00:08.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526085922/ownership.xml","form_type":"4"}},{"id":877223,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":31.42,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877222,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":10.16,"expiration_date":"2034-01-19","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877221,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":6.57,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877220,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":22.47,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877219,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":425000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":14.22,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877218,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":22.34,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877217,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":386015,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price."}],"balance_after":0,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":386015},"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":877216,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-27T20:19:36.000Z","date":"2026-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":474861,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the \"Merger Agreement\"), among Novartis AG (\"Novartis\"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the \"Merger Agreement\"), among Novartis AG (\"Novartis\"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-082275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526082275/ownership.xml","form_type":"4"}},{"id":932269,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-23T22:34:02.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":7993,"price":72.45,"value":579092.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."}],"balance_after":269007,"source":{"system":"sec-edgar","filing":"0001599901-26-000025","document":"wk-form4_1769207639.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990126000025/wk-form4_1769207639.xml","form_type":"4"}},{"id":932268,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-23T22:34:02.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":6394,"price":72.45,"value":463245.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."}],"balance_after":277000,"source":{"system":"sec-edgar","filing":"0001599901-26-000025","document":"wk-form4_1769207639.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990126000025/wk-form4_1769207639.xml","form_type":"4"}},{"id":942089,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-09T22:13:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":8576,"price":72.23,"value":619444.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."}],"balance_after":283394,"source":{"system":"sec-edgar","filing":"0001599901-26-000014","document":"wk-form4_1767996793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990126000014/wk-form4_1767996793.xml","form_type":"4"}},{"id":961989,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T13:27:38.000Z","date":"2025-12-18","kind":"gift","planned":false,"acquired":false,"shares":29159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a gift of shares to a Donor Advised Fund."}],"balance_after":291970,"source":{"system":"sec-edgar","filing":"0001599901-25-000219","document":"wk-form4_1766150855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000219/wk-form4_1766150855.xml","form_type":"4"}},{"id":961988,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T13:27:38.000Z","date":"2025-12-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":15742,"price":71.87,"value":1131377.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025."}],"balance_after":321129,"source":{"system":"sec-edgar","filing":"0001599901-25-000219","document":"wk-form4_1766150855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000219/wk-form4_1766150855.xml","form_type":"4"}},{"id":961987,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T13:27:38.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason."}],"balance_after":336871,"source":{"system":"sec-edgar","filing":"0001599901-25-000219","document":"wk-form4_1766150855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000219/wk-form4_1766150855.xml","form_type":"4"}},{"id":1046793,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-05T22:56:01.000Z","date":"2025-09-05","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option award is fully vested and exercisable as of the date hereof."}],"balance_after":1022015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001599901-25-000175","document":"wk-form4_1757112957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000175/wk-form4_1757112957.xml","form_type":"4"}},{"id":1046792,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-05T22:56:01.000Z","date":"2025-09-05","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":49.9487,"value":2497435.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.76 to $50.12. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305871,"source":{"system":"sec-edgar","filing":"0001599901-25-000175","document":"wk-form4_1757112957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000175/wk-form4_1757112957.xml","form_type":"4"}},{"id":1046791,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-05T22:56:01.000Z","date":"2025-09-05","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":1.24,"value":62000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."}],"balance_after":355871,"source":{"system":"sec-edgar","filing":"0001599901-25-000175","document":"wk-form4_1757112957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000175/wk-form4_1757112957.xml","form_type":"4"}},{"id":1052864,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T20:28:35.000Z","date":"2025-08-28","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option award is fully vested and exercisable as of the date hereof."}],"balance_after":1072015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001599901-25-000168","document":"wk-form4_1756499311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000168/wk-form4_1756499311.xml","form_type":"4"}},{"id":1052863,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-29T20:28:35.000Z","date":"2025-08-28","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":49.388,"value":1234700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $49.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305871,"source":{"system":"sec-edgar","filing":"0001599901-25-000168","document":"wk-form4_1756499311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000168/wk-form4_1756499311.xml","form_type":"4"}},{"id":1052862,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-29T20:28:35.000Z","date":"2025-08-28","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":1.24,"value":31000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person."}],"balance_after":330871,"source":{"system":"sec-edgar","filing":"0001599901-25-000168","document":"wk-form4_1756499311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000168/wk-form4_1756499311.xml","form_type":"4"}},{"id":1101139,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:50:00.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021373","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021373/rdgdoc.xml","form_type":"4"}},{"id":1194604,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-21T22:42:24.000Z","date":"2025-03-20","kind":"sale","planned":true,"acquired":false,"shares":31540,"price":31.0578,"value":979563.012,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 62,500 time-based restricted stock units (RSUs) that vested on March 19, 2025. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on September 19, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.06. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305871,"source":{"system":"sec-edgar","filing":"0001599901-25-000073","document":"wk-form4_1742596937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000073/wk-form4_1742596937.xml","form_type":"4"}},{"id":1296357,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-24T01:10:06.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":5659,"price":28.5946,"value":161816.8414,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.33. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":337411,"source":{"system":"sec-edgar","filing":"0001599901-25-000035","document":"wk-form4_1737681000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000035/wk-form4_1737681000.xml","form_type":"4"}},{"id":1296356,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-24T01:10:06.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":4738,"price":28.5932,"value":135474.5816,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.08. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":343070,"source":{"system":"sec-edgar","filing":"0001599901-25-000035","document":"wk-form4_1737681000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000035/wk-form4_1737681000.xml","form_type":"4"}},{"id":1306607,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-09T01:24:56.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029."}],"balance_after":165000,"derivative":{"exercise_price":31.42,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001599901-25-000021","document":"wk-form4_1736385890.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000021/wk-form4_1736385890.xml","form_type":"4"}},{"id":1306606,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-09T01:24:56.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":347808,"source":{"system":"sec-edgar","filing":"0001599901-25-000021","document":"wk-form4_1736385890.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990125000021/wk-form4_1736385890.xml","form_type":"4"}},{"id":1325348,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-19T23:15:58.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":31855,"price":32.66,"value":1040384.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 62,500 time-based restricted stock units (RSUs) that vested on December 17, 2024. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on June 17, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $32.66. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":265308,"source":{"system":"sec-edgar","filing":"0001599901-24-000205","document":"wk-form4_1734650152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000205/wk-form4_1734650152.xml","form_type":"4"}},{"id":1400871,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-24T01:01:05.000Z","date":"2024-09-19","kind":"grant","planned":true,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"As a result of the achievement of the Performance Condition, on September 19, 2024, an additional 25,000 PSUs were earned by the Reporting Person. On such date, such PSUs converted to time-based restricted stock units that will vest in full on March 19, 2025, subject to the Reporting Person's continued employment or service through such date."}],"balance_after":297163,"source":{"system":"sec-edgar","filing":"0001599901-24-000158","document":"wk-form4_1727139658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000158/wk-form4_1727139658.xml","form_type":"4"}},{"id":1400870,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-24T01:01:05.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":32880,"price":44.0001,"value":1446723.288,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on September 19, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":234663,"source":{"system":"sec-edgar","filing":"0001599901-24-000158","document":"wk-form4_1727139658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000158/wk-form4_1727139658.xml","form_type":"4"}},{"id":1400869,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-24T01:01:05.000Z","date":"2024-09-19","kind":"grant","planned":true,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the second performance objective (the Issuer's completion of a clinical event related to del-brax) (the Performance Condition)."}],"balance_after":267543,"source":{"system":"sec-edgar","filing":"0001599901-24-000158","document":"wk-form4_1727139658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000158/wk-form4_1727139658.xml","form_type":"4"}},{"id":1438796,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-07T21:46:57.000Z","date":"2024-08-06","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":461015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000127","document":"wk-form4_1723067208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000127/wk-form4_1723067208.xml","form_type":"4"}},{"id":1438795,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-07T21:46:57.000Z","date":"2024-08-06","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":43.3508,"value":1213822.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $44.51. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":205043,"source":{"system":"sec-edgar","filing":"0001599901-24-000127","document":"wk-form4_1723067208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000127/wk-form4_1723067208.xml","form_type":"4"}},{"id":1438794,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-07T21:46:57.000Z","date":"2024-08-06","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":233043,"source":{"system":"sec-edgar","filing":"0001599901-24-000127","document":"wk-form4_1723067208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000127/wk-form4_1723067208.xml","form_type":"4"}},{"id":1456159,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-11T20:07:00.000Z","date":"2024-07-09","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":489015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000115","document":"wk-form4_1720728412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000115/wk-form4_1720728412.xml","form_type":"4"}},{"id":1456158,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-11T20:07:00.000Z","date":"2024-07-09","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":39.9315,"value":1118082.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.70 to $40.52. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":205043,"source":{"system":"sec-edgar","filing":"0001599901-24-000115","document":"wk-form4_1720728412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000115/wk-form4_1720728412.xml","form_type":"4"}},{"id":1456157,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-11T20:07:00.000Z","date":"2024-07-09","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":233043,"source":{"system":"sec-edgar","filing":"0001599901-24-000115","document":"wk-form4_1720728412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000115/wk-form4_1720728412.xml","form_type":"4"}},{"id":1470798,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T20:25:48.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program. One-third of the option shares vest and become exercisable on June 24, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":29500,"derivative":{"exercise_price":19.19,"expiration_date":"2034-06-23","underlying":"Class A Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001437749-24-021091","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924021091/rdgdoc.xml","form_type":"4"}},{"id":1472009,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T21:01:17.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."}],"balance_after":40000,"derivative":{"exercise_price":4.19,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001846253-24-000050","document":"wk-form4_1719003670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625324000050/wk-form4_1719003670.xml","form_type":"4"}},{"id":1472008,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T21:01:17.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001846253-24-000050","document":"wk-form4_1719003670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625324000050/wk-form4_1719003670.xml","form_type":"4"}},{"id":1472007,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T21:01:17.000Z","date":"2024-06-18","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001846253-24-000050","document":"wk-form4_1719003670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625324000050/wk-form4_1719003670.xml","form_type":"4"}},{"id":1472006,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:01:17.000Z","date":"2024-06-18","kind":"exercise","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":68381,"source":{"system":"sec-edgar","filing":"0001846253-24-000050","document":"wk-form4_1719003670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625324000050/wk-form4_1719003670.xml","form_type":"4"}},{"id":1473149,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-20T22:47:54.000Z","date":"2024-06-17","kind":"grant","planned":true,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"As a result of the achievement of the Performance Condition, on June 17, 2024, an additional 62,500 PSUs were earned by the Reporting Person on such date. On such date, such PSUs converted to time based restricted stock units that will vest on December 17, 2024, subject to the Reporting Person's continued employment or service through such date."}],"balance_after":205043,"source":{"system":"sec-edgar","filing":"0001599901-24-000109","document":"wk-form4_1718923667.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000109/wk-form4_1718923667.xml","form_type":"4"}},{"id":1473148,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-20T22:47:54.000Z","date":"2024-06-18","kind":"sale","planned":true,"acquired":false,"shares":32074,"price":39.1295,"value":1255039.583,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on June 17, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price.  These shares were sold in multiple transactions at prices ranging from $39.05 to $39.13.  The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142543,"source":{"system":"sec-edgar","filing":"0001599901-24-000109","document":"wk-form4_1718923667.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000109/wk-form4_1718923667.xml","form_type":"4"}},{"id":1473147,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-20T22:47:54.000Z","date":"2024-06-17","kind":"grant","planned":true,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (PSUs).  Each PSU represents a contingent right to receive one share of the Issuer's common stock.  The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the first performance objective (the Issuer's initiation of the Phase 3 HARBOR trial for del-desiran) (the Performance Condition)."}],"balance_after":174617,"source":{"system":"sec-edgar","filing":"0001599901-24-000109","document":"wk-form4_1718923667.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000109/wk-form4_1718923667.xml","form_type":"4"}},{"id":1478925,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":false,"shares":35767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":517015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":35767},"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478924,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-13","kind":"exercise","planned":true,"acquired":false,"shares":164233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":552782,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":164233},"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478923,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":717015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478922,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-14","kind":"sale","planned":true,"acquired":false,"shares":35767,"price":40.0784,"value":1433484.1328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.22. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478921,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":true,"shares":35767,"price":1.24,"value":44351.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":147884,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478920,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-13","kind":"sale","planned":true,"acquired":false,"shares":164233,"price":40.076,"value":6581801.708,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.35. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478919,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-13","kind":"exercise","planned":true,"acquired":true,"shares":164233,"price":1.24,"value":203648.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":276350,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478918,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":100000,"price":35.7302,"value":3573020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $37.57. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1478917,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-14T22:58:21.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":true,"shares":100000,"price":1.24,"value":124000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":212117,"source":{"system":"sec-edgar","filing":"0001599901-24-000093","document":"wk-form4_1718405894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000093/wk-form4_1718405894.xml","form_type":"4"}},{"id":1489981,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T21:46:17.000Z","date":"2024-06-04","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":817015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000077","document":"wk-form4_1717623967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000077/wk-form4_1717623967.xml","form_type":"4"}},{"id":1489980,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-05T21:46:17.000Z","date":"2024-06-04","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":27.4207,"value":767779.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.87. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000077","document":"wk-form4_1717623967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000077/wk-form4_1717623967.xml","form_type":"4"}},{"id":1489979,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-05T21:46:17.000Z","date":"2024-06-04","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person."}],"balance_after":140117,"source":{"system":"sec-edgar","filing":"0001599901-24-000077","document":"wk-form4_1717623967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000077/wk-form4_1717623967.xml","form_type":"4"}},{"id":1524731,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-08T01:52:58.000Z","date":"2024-05-07","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":845015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000064","document":"wk-form4_1715133165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000064/wk-form4_1715133165.xml","form_type":"4"}},{"id":1524730,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-08T01:52:58.000Z","date":"2024-05-07","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":25.5375,"value":715050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000064","document":"wk-form4_1715133165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000064/wk-form4_1715133165.xml","form_type":"4"}},{"id":1524729,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-08T01:52:58.000Z","date":"2024-05-07","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":140117,"source":{"system":"sec-edgar","filing":"0001599901-24-000064","document":"wk-form4_1715133165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000064/wk-form4_1715133165.xml","form_type":"4"}},{"id":1536844,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-23T21:37:31.000Z","date":"2022-11-01","kind":"grant","planned":false,"acquired":true,"shares":39628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment is being filed to correct a Form 4 filed on November 3, 2022, which inadvertently understated the number of shares beneficially held by the Reporting Person following the transaction reported by 2,191 shares. The number reported in column 4 represents the correct number of shares acquired by the Reporting Person as of November 1, 2022, which included (1) 8,753 restricted stock units and (2) 16,704 earn-out shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the number of shares beneficially held by the Reporting Person as of the date of this filing, as adjusted for the administrative error identified in footnote 2."}],"balance_after":48381,"source":{"system":"sec-edgar","filing":"0001846253-24-000009","document":"wk-form4a_1713908240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625324000009/wk-form4a_1713908240.xml","form_type":"4/A","original_submission_date":"2022-11-03"}},{"id":1549548,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T22:16:42.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":873015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000049","document":"wk-form4_1712182590.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000049/wk-form4_1712182590.xml","form_type":"4"}},{"id":1549547,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-03T22:16:42.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":26.2471,"value":734918.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $26.97. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000049","document":"wk-form4_1712182590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000049/wk-form4_1712182590.xml","form_type":"4"}},{"id":1549546,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-03T22:16:42.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":140117,"source":{"system":"sec-edgar","filing":"0001599901-24-000049","document":"wk-form4_1712182590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000049/wk-form4_1712182590.xml","form_type":"4"}},{"id":1581046,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-12","kind":"exercise","planned":true,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":901015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1581045,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":false,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All unexercised shares subject to the option are fully vested and exercisable as of the date hereof."}],"balance_after":929015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1581044,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-12","kind":"sale","planned":true,"acquired":false,"shares":28000,"price":22.6315,"value":633682.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $22.71. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1581043,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-12","kind":"exercise","planned":true,"acquired":true,"shares":28000,"price":1.24,"value":34720.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":140117,"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1581042,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":84000,"price":21.3894,"value":1796709.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.33 to $21.54. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1581041,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-12T21:29:35.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":true,"shares":84000,"price":1.24,"value":104160.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":196117,"source":{"system":"sec-edgar","filing":"0001599901-24-000040","document":"wk-form4_1710278963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000040/wk-form4_1710278963.xml","form_type":"4"}},{"id":1596133,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:53:17.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All unexercised shares subject to the option are fully vested exercisable as of the date hereof."}],"balance_after":1013015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001599901-24-000038","document":"wk-form4_1709675574.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000038/wk-form4_1709675574.xml","form_type":"4"}},{"id":1596132,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T21:53:17.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":84000,"price":20.1346,"value":1691306.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $20.23. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 106,508 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":112117,"source":{"system":"sec-edgar","filing":"0001599901-24-000038","document":"wk-form4_1709675574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000038/wk-form4_1709675574.xml","form_type":"4"}},{"id":1596131,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T21:53:17.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":84000,"price":1.24,"value":104160.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the following securities previously acquired by the Reporting Person: (i) 106,508 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":196117,"source":{"system":"sec-edgar","filing":"0001599901-24-000038","document":"wk-form4_1709675574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000038/wk-form4_1709675574.xml","form_type":"4"}},{"id":1672990,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T20:13:50.000Z","date":"2024-01-20","kind":"grant","planned":true,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2024 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":300000,"derivative":{"exercise_price":10.16,"expiration_date":"2034-01-19","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001599901-24-000011","document":"wk-form4_1706040821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000011/wk-form4_1706040821.xml","form_type":"4"}},{"id":1672989,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-23T20:13:50.000Z","date":"2024-01-22","kind":"sale","planned":true,"acquired":false,"shares":5092,"price":10.13,"value":51581.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs on January 20, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such \"sell-to-cover\" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."}],"balance_after":44008,"source":{"system":"sec-edgar","filing":"0001599901-24-000011","document":"wk-form4_1706040821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000011/wk-form4_1706040821.xml","form_type":"4"}},{"id":1672988,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-23T20:13:50.000Z","date":"2024-01-20","kind":"grant","planned":true,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,709 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan."}],"balance_after":67209,"source":{"system":"sec-edgar","filing":"0001599901-24-000011","document":"wk-form4_1706040821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990124000011/wk-form4_1706040821.xml","form_type":"4"}},{"id":1782898,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T23:34:23.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":200000,"derivative":{"exercise_price":6.57,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001599901-23-000072","document":"wk-form4_1694561653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000159990123000072/wk-form4_1694561653.xml","form_type":"4"}},{"id":1843447,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-27T21:44:11.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant\ndate and (B) on the first anniversary of the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":4.81,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001846253-23-000084","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625323000084/primary_doc.xml","form_type":"4"}},{"id":1843446,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-27T21:44:11.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the\ndate of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the\ndate of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the\ndate of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001846253-23-000084","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625323000084/primary_doc.xml","form_type":"4"}},{"id":2032958,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-03","kind":"exercise","acquired":false,"shares":3221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter."}],"balance_after":1097015,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":3221},"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032957,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-02","kind":"exercise","acquired":false,"shares":45879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter."}],"balance_after":1100236,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":45879},"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032956,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-01","kind":"exercise","acquired":false,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter."}],"balance_after":1146115,"derivative":{"exercise_price":1.24,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032955,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":3221,"price":24.26,"value":78141.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":53352,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032954,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-03","kind":"exercise","acquired":true,"shares":3221,"price":1.24,"value":3994.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":56573,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032953,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":45879,"price":24.3628,"value":1117740.9012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.68.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":53352,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032952,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-02","kind":"exercise","acquired":true,"shares":45879,"price":1.24,"value":56889.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":99231,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032951,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":900,"price":24.2716,"value":21844.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.31.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":53352,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2032950,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:26:22.000Z","date":"2023-02-01","kind":"exercise","acquired":true,"shares":900,"price":1.24,"value":1116.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":54252,"source":{"system":"sec-edgar","filing":"0001209191-23-007092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123007092/doc4.xml","form_type":"4"}},{"id":2038511,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-02-01T19:10:03.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":37840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary."}],"balance_after":37840,"derivative":{"exercise_price":4.25,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":37840},"source":{"system":"sec-edgar","filing":"0001846253-23-000009","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625323000009/edgardoc.xml","form_type":"4"}},{"id":2038510,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T19:10:03.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":8753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSU fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary."}],"balance_after":46190,"source":{"system":"sec-edgar","filing":"0001846253-23-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000184625323000009/edgardoc.xml","form_type":"4"}},{"id":2047439,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-25T02:13:07.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":22.47,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-23-004768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123004768/doc4.xml","form_type":"4"}},{"id":2047438,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-25T02:13:07.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,352 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan."}],"balance_after":53352,"source":{"system":"sec-edgar","filing":"0001209191-23-004768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000120919123004768/doc4.xml","form_type":"4"}},{"id":2117916,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T21:30:45.000Z","date":"2022-11-10","kind":"purchase","acquired":true,"shares":15000,"price":2.92,"value":43800.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":36000,"source":{"system":"sec-edgar","filing":"0000899243-22-035698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035698/doc4.xml","form_type":"4"}},{"id":2117915,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T21:30:45.000Z","date":"2022-11-09","kind":"purchase","acquired":true,"shares":21000,"price":2.7427,"value":57596.7,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.71 to $2.79. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0000899243-22-035698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035698/doc4.xml","form_type":"4"}},{"id":2125608,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-11-04T01:15:38.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":37840,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on June 10, 2023."}],"balance_after":37840,"derivative":{"exercise_price":9.1,"expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":37840},"source":{"system":"sec-edgar","filing":"0000899243-22-035062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035062/doc4.xml","form_type":"4"}},{"id":2125607,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-11-04T01:15:38.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":13994,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":13994,"derivative":{"exercise_price":13.24,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":13994},"source":{"system":"sec-edgar","filing":"0000899243-22-035062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035062/doc4.xml","form_type":"4"}},{"id":2125606,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-11-04T01:15:38.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":10565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":10565,"derivative":{"exercise_price":13.49,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":10565},"source":{"system":"sec-edgar","filing":"0000899243-22-035062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035062/doc4.xml","form_type":"4"}},{"id":2125605,"issuer":{"id":5294,"kind":"organization","name":"OmniAb, Inc."},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-11-04T01:15:38.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":22616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. (\"Legacy OmniAb\"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the \"Merger Agreement\"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":22616,"derivative":{"exercise_price":12.37,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":22616},"source":{"system":"sec-edgar","filing":"0000899243-22-035062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000089924322035062/doc4.xml","form_type":"4"}}],"next_cursor":"2022-11-04T01:15:38.000000Z,2125605"}